Best GLP-1 for Belly Fat and Visceral Fat: What 12 Trials Actually Measured

Affiliate disclosure: The RX Index earns a commission from some provider links on this page, marked “sponsored.” It never changes which medicine the evidence supports. We separate drug evidence from provider access, and we show our work.

By Kaden Coziar, Founder & Managing Editor, The RX Index · Last verified: August 17, 2026 · Next re-verification: November 2026

The best GLP-1 for belly fat and visceral fat, among FDA-approved choices and based on the strongest direct obesity-dose evidence, is tirzepatide (sold as Zepbound). In the only trial that compared Zepbound-range tirzepatide with Wegovy-range semaglutide in adults with obesity and no diabetes, waists shrank 18.4 cm (about 7.2 inches) versus 13.0 cm (about 5.1 inches) over 72 weeks. No GLP-1 removes belly fat only. And Zepbound has never been tested against the newer, higher-dose Wegovy 7.2 mg.

Retatrutide now has the largest reported waist result: 24.1 cm (about 9.5 inches) at 80 weeks on its top dose. But that is company-released Phase 3 topline data, not a completed peer-reviewed paper, and retatrutide is still investigational. Lilly says it is legally available only to people in its clinical trials. That changes the biggest number on the page. It does not change which medicine a patient can actually ask for today.

Here's the part almost nobody will tell you.

That “40% visceral fat reduction” stat you keep seeing for tirzepatide? It's real, but it came from a body-composition substudy of 160 people, using DXA software that estimates deep belly fat instead of measuring it directly. We went looking for what semaglutide did with CT imaging. In a different trial, semaglutide 2.4 mg came in at 40.0%.

Same size. Different machine. Put those two numbers next to each other and it changes how you should read every ranking on the internet — including ours.

So we built the evidence map this search needs: 12 trials in all, including two active-drug head-to-head trials, the new retatrutide Phase 3 waist result, and a nine-trial scan ledger showing which method produced each visceral-fat number and whether belly fat was the trial's real goal. Then we'll show you how to track your own middle without pretending a tape measure is an MRI.

Best for you if

• You want the largest measured waist reduction proven between available FDA-approved choices, and you can take a weekly shot
• Your plan covers Zepbound, or you can use a self-pay path you can keep affording
• You have obesity, or extra weight plus a related health problem such as high blood pressure or sleep apnea

Not for you if

• Your BMI is in the normal range and your goal is only how your stomach looks (this is not what these medicines are approved for — we'll explain what to do instead)
• You're pregnant or trying to become pregnant
• You or a family member has had medullary thyroid cancer, or you have MEN2 (a rare inherited hormone condition)
• You want a guaranteed flat stomach. Nothing here can promise that

The 20-second answer

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation. Independent guidance for choosing your GLP-1 path.

The right GLP-1 provider isn't the same for everyone — it depends on your state, your insurance and formulary, whether you want an FDA-approved or compounded medication, your preferred treatment path (injection or oral), and your budget. Because a general answer can't resolve those for you, use The RX Index's Find My GLP-1 Path tool to get a personalized provider match with source-verified pricing before you choose.

### ➡️ Start here if you want the short version Get your personalized GLP-1 path in 60 seconds → Match by state, coverage, injection or pill, and budget. No email needed to see your result.

On this page: the head-to-head winner · whether Wegovy 7.2 changes it · what retatrutide changes · the nine-trial visceral-fat scan ledger · why the percentages can't be ranked · pills, compounded medicines, and peptides · who qualifies · risks · which one fits you · how to track your waist · how long it takes · what happens if you stop · how we decided · FAQ

Which GLP-1 is best for belly fat?

Tirzepatide has the strongest direct evidence for the obesity-dose decision. In SURMOUNT-5, a 72-week trial of 751 adults, tirzepatide reduced body weight by 20.2% and waist size by 18.4 cm, compared with 13.7% and 13.0 cm for semaglutide. It is the only trial that compared Zepbound-range tirzepatide with Wegovy-range semaglutide in adults with obesity and no diabetes.

Everything else you'll read about GLP-1s and belly fat compares numbers from separate trials. That's like timing two runners on different tracks, on different days, with different stopwatches, and declaring a winner.

SURMOUNT-5 used one track.

What SURMOUNT-5 actually did

• 751 adults with obesity and no type 2 diabetes
• Tirzepatide at the highest dose each person could tolerate (10 mg or 15 mg) versus semaglutide at 1.7 mg or 2.4 mg
• 72 weeks
• Published in the New England Journal of Medicine in 2025
• 92.8% of the semaglutide group received at least one 2.4 mg dose, and 89.3% of the tirzepatide group received at least one 15 mg dose

Results: −20.2% body weight and −18.4 cm waist on tirzepatide, versus −13.7% and −13.0 cm on semaglutide.

That waist gap was 5.4 cm, or about 2.1 inches. It is a real difference measured in the same trial, not a subtraction across two unrelated studies.

The earlier head-to-head trial most pages leave out

SURMOUNT-5 was not the first time tirzepatide and semaglutide met in one trial. SURPASS-2 compared tirzepatide 5, 10, and 15 mg with semaglutide 1.0 mg for 40 weeks in 1,879 adults with type 2 diabetes taking metformin. Average waist change was −6.9 cm, −9.6 cm, and −9.9 cm with the three tirzepatide doses, versus −5.6 cm with semaglutide 1.0 mg.

That earlier trial points in the same direction. It does not settle the weight-management decision because it studied diabetes, ran for 40 weeks, and used semaglutide 1.0 mg rather than Wegovy 1.7, 2.4, or 7.2 mg. SURMOUNT-5 is the direct trial that answers the Zepbound-versus-standard-Wegovy obesity question.

How we rank evidence on this page

This matters more than any single number, so we label every piece of evidence with one of four tags. You'll see them throughout.

We ranked by how direct the evidence was — not by whichever number looked biggest.

What the head-to-head did not prove

Four honest limits, all from the trial itself:

1. It was open-label. Everyone knew which drug they were getting. That can change behavior even when weight and waist are measured.
2. The semaglutide plan allowed 1.7 mg or 2.4 mg as the maximum tolerated dose. But this was not a mostly low-dose group: 92.8% received at least one 2.4 mg dose.
3. It did not include Wegovy 7.2 mg, which did not exist yet.
4. It did not scan anyone's belly fat. Waist size is a measurement of you from the outside. More on that below.

RX Index verdict: Zepbound is the best answer when “best” means the biggest measured waist reduction proven against an available standard-dose Wegovy path. It is not automatically the winner for every person, every budget, or against the newest semaglutide dose.

For the broader question of total weight loss, see our best GLP-1 for weight loss comparison.

Does the new Wegovy 7.2 mg dose change the answer?

Yes — it makes it much closer. The FDA approved higher-dose semaglutide (Wegovy 7.2 mg, branded Wegovy HD) in March 2026. In its own trial, it reduced body weight by 18.8% and waist size by 17.5 cm. But it has never been compared directly with Zepbound, so no one can honestly say which wins.

Look at those two waist numbers side by side.

• Tirzepatide, SURMOUNT-5: −18.4 cm
• Wegovy 7.2 mg, its own FDA label study: −17.5 cm

That's a gap of 0.9 cm. About one-third of an inch. Across two different trials.

Do not subtract those numbers and call the difference a drug advantage. Different people, different years, different math. The honest read is that these two are close enough that your tolerance, coverage, and ability to stay on treatment matter more than that cross-trial gap.

What the Wegovy label reports

Straight from the current FDA prescribing information for Wegovy (verified August 17, 2026):

Tag: vs placebo and vs a lower dose of itself.

One number, three versions — and why we use the label's

Here's a detail most summaries skip. The same trial has been reported three ways:

• −18.8% in the FDA label
• −18.7% in the published paper's treatment-policy analysis, which counts everyone who started no matter what happened after
• −20.7% in the published paper's trial-product analysis, which estimates what happened while people stayed on treatment

All three are real. They answer slightly different questions. We use the FDA label figure (18.8%) as our public comparison, because it is the regulator-reviewed number a reader can check in the current prescribing information.

If you see 20.7% on another site with no explanation, that's why.

The tradeoff most pages skip

Higher dose, more side effects. The Wegovy label reports dysesthesia — odd skin sensations such as tingling, burning, pain, or extra-sensitive skin — in 22% of people at 7.2 mg, versus 6% at 2.4 mg and 0.3% on placebo.

Among the 288 people who reported dysesthesia at 7.2 mg, 23% had their dose reduced, 8% paused treatment, 2% stopped it, and 18% had not reported recovery by the end of the trial. Of 38 people who recovered after a treatment change and then went back up to 7.2 mg, 17 had the symptom return.

A stronger dose you can't stand is weaker than a moderate dose you stay on.

Both Zepbound and Wegovy are FDA-approved. Coverage still depends on your plan. Before you spend anything, find out what yours says. Check your coverage for Zepbound or Wegovy with Ro → (sponsored) Free coverage check for select injectable products. No card required to see the coverage result.

Does retatrutide now beat Zepbound for belly fat?

Retatrutide has the biggest reported waist number, but it does not replace Zepbound as the best available answer. In May 2026, Lilly reported that retatrutide 12 mg cut average waist size by 24.1 cm over 80 weeks in TRIUMPH-1. Retatrutide is still investigational, the result is company topline data, and no trial has compared it directly with Zepbound or Wegovy 7.2 mg.

TRIUMPH-1 randomized 2,339 adults with obesity, or overweight plus a related condition, and no diabetes. All groups also received the trial's diet and activity support.

Tag: vs placebo, company topline, investigational.

Here's the status gate that keeps the page honest:

• Largest reported waist change: retatrutide 12 mg, −24.1 cm
• Strongest direct proof between medicines people can get now: Zepbound, −18.4 cm versus −13.0 cm for standard-dose Wegovy
• Unanswered question: retatrutide versus Zepbound versus Wegovy 7.2 mg in one trial

Retatrutide is a triple GIP, GLP-1, and glucagon receptor agonist. Lilly says it is legally available only to people in its clinical trials. A website selling “retatrutide” today is not selling an FDA-approved retatrutide product.

It changes the biggest number. It does not create a treatment path you can use today.

Do GLP-1 medications actually reduce visceral fat?

Yes. Nine randomized trials or scan substudies have used DXA, MRI, or CT to examine the fat deep inside the abdomen. Most showed that visceral fat fell along with body weight. But they did not all measure the same thing, use the same unit, or ask the same research question.

First, the two-sentence anatomy lesson, because the whole page depends on it.

Subcutaneous fat is the fat right under your skin. It's the fat you can pinch. Visceral fat is deeper, packed in around your liver, pancreas, and intestines. You can't pinch it or see it directly, and higher amounts are more closely tied to type 2 diabetes, high blood pressure, and heart disease.

When your stomach sticks out, you're usually looking at a mix of subcutaneous fat, visceral fat, muscle, organs, gas, and sometimes loose skin. That's why the mirror is a terrible measuring tool.

The 12-trial evidence map

We counted a trial only when it met one of these rules:

1. It directly compared two available medicines and reported waist change.
2. It reported a new Phase 3 waist result that could change the answer, even if the medicine was still investigational.
3. It was a randomized adult trial or substudy that measured abdominal visceral fat with CT, MRI, or DXA and reported data by August 17, 2026.

That produces 12 trials total:

• 2 active-drug head-to-head waist trials: SURMOUNT-5 at weight-management dose ranges, and SURPASS-2 at diabetes doses
• 1 investigational Phase 3 waist trial: TRIUMPH-1
• 9 visceral-fat imaging trials: the ledger below

The scan ledger has ten rows because STEP 6 reported two semaglutide doses from the same trial.

The visceral-fat evidence ledger

This is the table we built for this page. Read the method and unit columns before you compare any two rows.

VAT means visceral adipose tissue. VFA means visceral fat area. CT and MRI image the abdominal fat compartment; DXA uses software and a selected body region to estimate it. STEP 6 appears twice because its 1.7 mg and 2.4 mg doses were measured in the same CT subset. Every other row is a separate trial.

Three things this table shows that a simple ranking hides

1. Dose can change the result inside the same trial. STEP 6 used the same CT method, population, and 68-week clock for both semaglutide doses. Visceral fat area fell 22.2% at 1.7 mg and 40.0% at 2.4 mg. That is a cleaner dose comparison than putting an Ozempic result from one study beside a Wegovy result from another.

The SUSTAIN 8 result does not show that semaglutide 1.0 mg changed visceral fat by less than 1%. It reported a change of 0.2 kg and 0.9 percentage points, not a 0.9% relative loss. Those units cannot be dropped into the percentage ranking above.

2. In two trials, the lifestyle-plus-placebo group's belly fat went up. Every placebo group still received the trial's diet and activity support. Here's what happened:

Read that last row again. In a large, well-run trial, people getting real diet and activity support saw their deep belly-fat estimate rise 7.4% over 72 weeks.

If you've been trying and your middle isn't moving, you are not broken and you are not lazy. In some carefully supported groups of people, it goes backwards. That's not us being nice. That's the placebo arm.

3. Only one trial in this ledger made visceral fat the main endpoint. Just one. And it tested liraglutide — an older GLP-1 with smaller average weight-loss results than the newer medicines. Ian Neeland and colleagues designed a 40-week MRI trial where reducing visceral fat was the main goal. Result: −12.49% on liraglutide versus −1.63% on placebo.

Every other visceral-fat number on this page — including tirzepatide's famous 40.1% — came from a secondary, exploratory, or substudy analysis of a trial built around another main question.

That's not a scandal. It's just the truth about how strong this evidence really is, and you deserve to know it before you spend hundreds of dollars a month.

Why can't the visceral-fat percentages be ranked?

Because several measurement approaches and units are hiding behind one phrase. Tirzepatide's 40.1% is a DXA software estimate from one part of the trunk. Semaglutide's 40.0% came from a CT image of abdominal visceral-fat area. SUSTAIN 8 reported kilograms and percentage points instead of a relative percentage. Those are not interchangeable scores.

Here's what “visceral fat” actually meant in these trials.

The STEP 1 methods deserve a second look. The selected region could be the L4 area, the android region in men, or the gynoid region in women, depending on the scanner and site. The gynoid region is around the hips and upper thighs. That does not make the study useless. It makes its 27.4% figure a poor contestant in a cross-trial belly-fat race.

And the tirzepatide figure? The study authors describe visceral fat as estimated, not directly measured. The body-composition substudy was planned, but the number still comes from DXA software, pooled tirzepatide doses, and a different protocol from every semaglutide scan study.

The comparison our ledger makes visible

The common internet ranking says tirzepatide beats semaglutide on visceral fat by about 13 points because it compares tirzepatide's 40.1% with semaglutide's 27.4% STEP 1 DXA figure. But use semaglutide's CT result instead and the gap disappears.

We are not claiming semaglutide is better. We're saying the ranking depends heavily on the instrument, region, population, and analysis — not only the drugs. Two different populations, two different methods, no shared protocol.

That's exactly why our available-drug verdict rests on SURMOUNT-5's waist result instead. One trial. One protocol. One tape-measure method. Same week.

It's a smaller, less exciting claim. It's also the only one that holds up.

The RX Index unit rule

Before comparing two belly-fat numbers, ask four questions:

1. Is each number relative percent, kilograms, liters, square centimeters, or percentage points?
2. Did CT, MRI, or DXA produce it?
3. Was the body region the same?
4. Were the drugs tested in the same trial?

A different unit is a stop sign. A different method is a warning sign. A different trial is context, not a winner.

What about pills, compounded versions, and peptides like tesamorelin?

There are now two FDA-approved daily pills for chronic weight management. The Wegovy 25 mg tablet reduced waist size by 12.2 cm in its label study. Foundayo has a DXA subgroup showing a 19.0% pooled visceral-fat reduction. Compounded semaglutide and tirzepatide have no qualifying published visceral-fat scan data that we could locate. Tesamorelin is FDA-approved to reduce excess abdominal fat only in adults with HIV-associated lipodystrophy.

The pills

Wegovy 25 mg tablet. From the current FDA label: over 64 weeks, −13.6% body weight and −12.2 cm waist, versus −2.4% and −2.8 cm on placebo. Tag: vs placebo.

Foundayo (orforglipron). A once-daily pill. In the ATTAIN-1 DXA subgroup, the pooled active-dose groups showed −19.0% visceral fat, while the placebo group's estimate went up 7.4%. The dose-by-dose range was −12.6% to −28.2%. Tag: scan study, DXA.

The approved Foundayo label uses 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, and 17.2 mg tablets. Older trial reports may show different development-dose numbers. Do not try to convert or choose a dose from a research table; the label uses a step-up schedule and the prescriber chooses the path.

A pill is not automatically weak. And if a needle is what's stopping you from starting, a pill you actually take beats a shot you never fill.

Compounded semaglutide and tirzepatide

Two things, and we're not going to soften either one.

First: there is no qualifying published scan evidence for compounded products. Every number on this page comes from a trial of a specific FDA-approved or investigational medicine, at a specific dose, made under that trial's protocol. Those results belong to what was tested. We don't extend them to a compounded version, and no one else should either. As of August 17, 2026, we located no qualifying visceral-fat imaging result for any compounded semaglutide or tirzepatide formulation.

Second: compounded drugs are not FDA-approved. FDA does not review a compounded product for safety, effectiveness, or quality before it reaches a patient. Compounding can be legal when the facts and the prescription fit the law, but “compounded” and “FDA-approved” are not interchangeable labels.

Quick definitions, because these terms get thrown around:

• A 503A pharmacy compounds for an identified patient with a prescription and must meet the conditions in section 503A.
• A 503B outsourcing facility can make larger batches, but it has a different set of federal conditions.

Compounders had more room to make copies while the FDA shortage list included these drugs. The FDA declared the tirzepatide injection shortage resolved in December 2024 and the semaglutide injection shortage resolved in February 2025. The shortage-related enforcement periods later ended: March 19, 2025 for 503B tirzepatide and May 22, 2025 for 503B semaglutide.

As of August 17, 2026, tirzepatide and semaglutide appeared on neither the FDA drug-shortage list nor the 503B bulks list. On April 30, 2026, the FDA announced a proposal not to add semaglutide, tirzepatide, and liraglutide to the 503B bulks list after finding no clinical need for outsourcing facilities to compound them from bulk substances. The notice was published May 1. The original comment deadline was June 30, 2026, and the FDA extended it to July 30, 2026. We found no later final Federal Register determination as of this page's verification date.

That proposal is about the 503B bulks-list route. It is not a blanket statement that every patient-specific 503A prescription is illegal. But a 503A copy generally needs a prescriber-documented change that produces a significant difference for the individual patient, along with the other legal conditions. The FDA guidance gives clinical examples such as a needed dosage form or avoiding an allergen; a lower price by itself does not identify that kind of patient-specific clinical difference.

We're not telling you no compounded product can produce weight loss. We're telling you that on this specific question — deep belly fat, measured by a scanner — there is nothing to show you. If cost is the reason you're looking at compounded options, read our current price and access comparison first, because manufacturer self-pay programs can now undercut a provider-plus-compounding bill in some cases.

Tesamorelin (Egrifta), and why peptide sites rank for this search

If you searched “best peptide for visceral fat,” you probably landed on a page selling research chemicals. So let's answer it honestly.

Tesamorelin is the only FDA-approved medicine we found with an indication written specifically around reducing excess abdominal fat. It is not a GLP-1. It is a growth-hormone-releasing factor analog. And the approval covers one narrow group: adults with HIV-associated lipodystrophy, a condition in which body fat gets redistributed.

Its FDA label says it is not indicated for weight-loss management, because it has a weight-neutral effect.

So: real drug, real approval, real abdominal-fat indication — for a condition most people making this search do not have. We're not publishing doses, protocols, or where to buy peptide versions of anything. No FDA-approved tesamorelin product is indicated for general belly fat, and an online “research use only” vial is not the approved medicine.

Can you take a GLP-1 just to lose belly fat?

Not as a cosmetic treatment for one body part. These medicines are approved for chronic weight management in adults with obesity, or with excess weight plus a related health condition. A clinician decides whether the expected benefit outweighs the risks for you specifically.

Here's who the adult trials and weight-management labels generally cover:

• Obesity, usually meaning a BMI of 30 or higher
• Overweight — BMI 27 or higher — plus at least one weight-related condition, such as high blood pressure, abnormal cholesterol, sleep apnea, or heart disease

BMI is a rough tool and clinicians know it. Waist size can add useful health information. But a website can't determine your eligibility from a photo or a tape measure, and neither can we.

If your BMI is normal and your stomach still bothers you

We're going to be straight with you, because this is one of the most common versions of this search.

A prescription GLP-1 is not the labeled path for shrinking one body area you don't like. And the honest reason isn't just rules — it's that a stomach that sticks out at a normal weight can be caused by bloating, constipation, a hernia, posture, muscle separation after pregnancy, loose skin, fat distribution, or the effect of another medication.

Taking a strong weekly or daily drug for a problem it wasn't designed to solve is how people end up with side effects and no answer.

What to do instead: see a clinician about the specific concern. If they find a waist measurement or metabolic problem that changes your medical risk, that's a medical conversation with real options. If it's bloating, constipation, a hernia, or muscle separation, a GLP-1 was never going to fix the cause.

Who needs a clinician conversation before anything else

From the current FDA labels:

• Pregnancy, trying to become pregnant, or planning pregnancy. Weight-loss treatment offers no benefit during pregnancy. The labels give medicine-specific stopping instructions.
• Personal or family history of medullary thyroid cancer, or MEN2. This is a contraindication for Zepbound, Wegovy, and Foundayo — meaning do not use them.
• A history involving pancreatitis, gallbladder disease, kidney problems, or severe stomach-emptying problems
• Diabetes medicines that can drop your blood sugar too low
• Surgery or deep sedation coming up
• You're already on another product containing semaglutide, another GLP-1 receptor agonist, or tirzepatide. Don't stack them.

If you're in the labeled group, the next question is which treatment path your state, plan, and budget actually allow. See which GLP-1 paths fit your situation → Free. No email required to see your result.

What are the risks and downsides?

Stomach and gut side effects are the most common issue across these medicines — nausea, vomiting, diarrhea, constipation, and abdominal pain. The labels also carry serious warnings, and the highest dose is not automatically the right dose for you. The medicine with the biggest average result is the wrong choice if you can't stay on it.

What's shared across the class

• Gut side effects, often worst while your dose is going up
• Dehydration and kidney injury risk if vomiting or diarrhea keeps going
• Gallbladder problems and pancreatitis warnings on the labels
• Slower stomach emptying, which is why your care team needs to know before surgery or deep sedation
• Dose escalation takes months. You do not start at the trial's top dose
• Cost and coverage, which can decide whether a long-term plan is real or imaginary

Tirzepatide (Zepbound) specifics

• Weekly injection. There is no FDA-approved tirzepatide pill on the market
• Contraindicated with a personal or family history of medullary thyroid cancer, or MEN2
• Stop it when pregnancy is recognized
• The one almost nobody mentions: the label warns that tirzepatide can reduce how well birth-control pills work. It recommends switching to a non-oral method or adding a barrier method for 4 weeks after starting and for 4 weeks after every dose increase. If you're on the pill, this is a real conversation, not a footnote.

Wegovy 7.2 mg specifics

• More nausea, vomiting, and constipation than 2.4 mg in the label study
• Dysesthesia in 22% of people, versus 6% at 2.4 mg and 0.3% on placebo
• Some people needed a dose reduction, pause, or permanent stop because of it
• A higher dose is not better if it puts you on the couch

A note on muscle

Losing a lot of weight means losing some lean tissue too. That's true of every major weight-loss method, including surgery and dieting. It is worth planning for with enough protein, resistance training if your clinician clears it, and a sensible pace — and it's a big enough topic that we gave it its own page. See our breakdown of lean-mass loss by drug for the numbers by molecule.

Which GLP-1 fits your situation — and where should you start?

The average winner isn't automatically your winner. Coverage, injection versus pill, other health conditions, side-effect tolerance, and whether you can stay on treatment for a year all outweigh a 1 cm difference pulled from separate trials.

If you are paying cash, check the manufacturer first

This is the step affiliate pages are tempted to skip.

As of August 17, 2026, LillyDirect listed Zepbound self-pay prices of $299 per month for 2.5 mg, $399 for 5 mg, and $449 for 7.5 mg through 15 mg when the higher doses are refilled within 45 days. Terms and eligibility apply. The page also says a “month” is 28 days, 2.5 mg is a starting dose rather than a maintenance dose, and pen needles or vial supplies may be separate depending on the format.

NovoCare listed these Wegovy injection prices:

• $199 per month for the first two fills at 0.25 mg and 0.5 mg for eligible new self-pay patients who start by December 31, 2026
• Then $349 per month for Wegovy 0.25 mg through 2.4 mg
• $399 per month for Wegovy HD 7.2 mg

The Wegovy tablet page listed $149 for 1.5 mg, a time-limited $149 offer for 4 mg through August 31, 2026 before a listed $199 price, and $299 for 9 mg and 25 mg, subject to the program's terms.

Prices change. Dose matters. Eligibility rules matter. A headline that says “starts at $149” may describe only the first or lowest dose. Use our dated GLP-1 price and access tracker before you choose a cash path.

Where to start when you need care or insurance help: Ro

For FDA-approved medicine access, Ro is our primary provider recommendation on this page when the reader needs a clinician, an insurance check, or help with prior authorization — because every treatment result in our available-drug verdict belongs to an FDA-approved branded product.

What we checked on Ro's public pricing page on August 17, 2026:

“Verified” here means we matched the claim to Ro's public page while logged out. We did not enroll as a patient, test its clinical care, or verify any individual insurance result.

The honest downside, and why Ro can still fit

Ro is not the cheapest way to get the same medication when you are paying cash. Its membership fee sits on top of the medicine price. If your top goal is the lowest total cash cost and you already have a workable prescribing path, start with the manufacturer's program instead — here's our cost comparison.

The reason Ro can still earn the click is different: it puts the clinician, coverage check, prior-authorization work, and ongoing program in one place. That can be worth more than the membership fee when insurance paperwork is the wall between you and the medicine.

Does that sound like your situation? Then find out what your plan says before you commit to medication. Check eligibility and coverage for Zepbound or Wegovy with Ro → (sponsored) Membership starts at $39 for the first month, then as low as $74/month with an annual plan paid upfront. Medication is billed separately. Verified August 17, 2026.

If you'd rather choose your own clinician: Sesame

Some people don't want the same membership setup — they want to see the clinician path and choose. Sesame's Success by Sesame subscription started at $59 per month with an annual subscription as of August 17, 2026. Its public page said the subscription includes telehealth visits, unlimited messaging, and ongoing care from a provider of your choice. Medication is not included.

The same page listed FDA-approved options including Foundayo, Wegovy, and Zepbound, subject to the clinician's decision, eligibility, and availability.

Compare current FDA-approved options with a Sesame clinician → (sponsored)

How will you know if your belly fat is going down?

You can't measure visceral fat at home. What you can track is your waist, and one useful way to read it is your waist divided by your height. NICE classifies 0.40 to 0.49 as healthy central adiposity, 0.50 to 0.59 as increased central adiposity, and 0.60 or higher as high central adiposity for adults with a BMI under 35.

The plain-English version of that guidance: try to keep your waist under half your height.

How to measure so the number means something

1. Use the same soft tape every time.
2. Find the bottom of your ribs and the top of your hip bones. Measure halfway between them.
3. Keep the tape level all the way around, snug but not digging in.
4. Stand normally. Don't suck your stomach in.
5. Breathe out normally — don't force all the air out.
6. Use a similar time of day and similar clothing, ideally before eating.
7. Measure twice. If the readings differ, use the average.
8. For your own trend, compare points about eight weeks apart. That is our practical tracking interval, not a NICE rule. Short gaps are easier to distort with food, bowel changes, and water.

What your ratio means

Use the same unit for both numbers. Inches divided by inches works. Centimeters divided by centimeters works.

Source: NICE guideline NG246. The adult waist-to-height classification is used when BMI is under 35 and can be applied across sexes and ethnic groups. It does not diagnose a disease or replace a clinical assessment.

🧮 The GLP-1 waist-change worksheet

We use a waist worksheet instead of a “visceral-fat calculator,” because a tape measure cannot measure visceral fat and we're not going to pretend it can.

Formula: waist ÷ height = waist-to-height ratio

Example: a 36-inch waist divided by a 70-inch height equals 0.514. That sits in the increased-central-adiposity band.

For each follow-up, calculate:

• Waist change: new waist minus baseline waist
• Weight change: new weight minus baseline weight
• Ratio change: new ratio minus baseline ratio

A negative waist change means your waist got smaller. Do not compare your number with a trial average until you also check the trial's dose, length, population, and analysis. The average is not a promise for you.

This worksheet tracks your waist trend. It does not measure visceral fat, diagnose anything, predict your result, set a goal waist, or tell you to change your dose. Keep it on your device or print it. You do not need to send health measurements to us to use it.

Why waist is useful without pretending it is an MRI

The retatrutide MRI substudy gives us a real check on the tape measure. At week 24, the change in liver fat moved with the change in waist circumference at r = 0.652 and with the change in visceral fat at r = 0.792. At week 48, those correlations were 0.601 and 0.745.

“r” shows how tightly two measurements move together. A value of 1.0 would mean they move together perfectly. These numbers do not turn waist into a visceral-fat scan, and they do not give a direct waist-to-VAT conversion. They show that waist is useful signal, not random noise.

Get your baseline today, then choose a treatment path that fits your state, coverage, and budget. Match my situation to a GLP-1 treatment path →

How long does belly-fat loss take — and what if your stomach doesn't change?

Plan in months, not weeks. The waist and scan results on this page were generally measured after 40 to 80 weeks, and part of that time is spent slowly increasing the dose. In the retatrutide MRI substudy, most liver-fat improvement happened in the first 24 weeks, while visceral and skin-level abdominal fat kept falling through week 48.

That finding is useful enough to say again in plain terms.

In that trial, liver fat slowed first. Belly fat kept going.

Near-maximal liver-fat improvement appeared around a 20% reduction in body weight. But visceral and subcutaneous abdominal fat volumes kept dropping after that point while weight loss continued.

That does not prove every medicine or every person follows the same clock. It does prove that one body-fat compartment can slow while another keeps changing. A flat-looking month does not tell you what happened around your organs.

If the scale is moving but your stomach isn't

Four real explanations, in the order worth checking:

1. Measurement drift. Different tape position, different time of day, different clothes. Fix the method before you conclude anything.
2. Loose skin. After a large or long weight loss, skin doesn't always follow. Soft, pinchable tissue can be skin plus remaining subcutaneous fat, not visceral fat.
3. Bloating and constipation. These are common side effects of the medicines on this page, and they can add real inches to a waist measurement for a while. Your stomach can look bigger during a week when fat loss is still happening.
4. Where your body stores fat. People lose in different orders. Faces and arms show small changes sooner because a small change there is easy to see. That does not reveal what happened deeper in the abdomen.

What not to do at a plateau

Don't raise your own dose. Don't stack a second GLP-1. Don't judge a 40-to-80-week treatment on six weeks of mirror time.

And call your clinician instead of assuming, if you have: severe or lasting abdominal pain, ongoing vomiting, a waist that is growing while your weight is falling, or a new bulge or one-sided change in your belly. Those are worth a real evaluation, not another search result.

Will the belly fat come back if you stop?

Weight regain is common after stopping. In the STEP 1 extension, people who stopped semaglutide had lost 17.3% of their weight at week 68, then regained 11.6 percentage points by week 120 — leaving them 5.6% below where they started. Many heart and metabolic measures moved back toward baseline.

This is the least fun fact on the page and the most important one for your wallet.

These medicines treat a long-term condition. Their effects on appetite and weight regulation do not stay fully switched on after the medicine stops. The STEP 1 extension did not scan visceral fat, so it cannot tell us the exact amount of deep belly fat that returned. It does tell us that most of the lost weight came back over the following year.

What that means practically: decide your long-term plan before you start, not at month nine when your savings offer expires. If you're likely to stop because of cost, the coverage question isn't a detail — it's the whole decision.

That's the real reason we put a coverage check and direct-pay prices earlier on this page instead of a “buy now” button.

How we chose the winner

We ranked evidence by how direct it was, not by which number looked biggest. A trial comparing two available drugs in the same people beat separate trials. FDA labels beat press coverage. Scan studies answered whether deep fat moved. Numbers from different trials were used as context and never as a score. Investigational topline data could change the research map without becoming a treatment recommendation.

Our order of trust:

1. Head-to-head trial evidence between available medicines
2. Current FDA prescribing information
3. Peer-reviewed CT, MRI, and DXA studies
4. Placebo-controlled trial evidence
5. Company topline data for a major new trial, clearly labeled and never treated as peer reviewed
6. Cross-trial context, always labeled as such
7. Current, dated commercial facts such as prices and what a provider lists
8. Our editorial judgment, built only on the seven above

A note on our scoring: the RX Index Score we use to evaluate providers rates them on exactly five pillars, in this order — clinical legitimacy, care quality, transparency, access, and cost. That framework rates providers. It does not pick medicines. Medicine verdicts on this page come from the trial and label evidence above.

✅ What we actually verified

Verified August 17, 2026.

We opened or checked the full papers, posted results, labels, or official primary pages for:

• SURMOUNT-5 and its 18.4 cm versus 13.0 cm obesity-dose head-to-head waist result
• SURPASS-2, the earlier diabetes-dose head-to-head trial
• TRIUMPH-1's May 2026 company topline report and retatrutide's investigational status
• The current Wegovy label, including the 7.2 mg injection study, the 25 mg tablet study, and the 22% dysesthesia rate
• The current Zepbound and Foundayo labels
• The SURMOUNT-1 body-composition paper and correction
• The retatrutide Phase 2a MRI substudy
• STEP 6, STEP UP, STEP 1, SURPASS-3 MRI, the liraglutide MRI trial, ATTAIN-1, and SUSTAIN 8
• The STEP 1 withdrawal extension
• The current Egrifta WR label and NICE guideline NG246
• FDA and Federal Register pages on shortage-related compounding and the proposed 503B bulks-list decision
• The public pricing pages for LillyDirect, NovoCare, Ro, and Sesame

We recorded which method and unit produced every visceral-fat number. We did not convert between kilograms, percentage points, areas, volumes, and relative percentages. We did not average across trials. Where a result was a subgroup, substudy, post hoc analysis, or company topline release, the page says so.

We did not: take these medicines, enroll as patients, review anyone's chart, independently test a provider's care, or verify an individual insurance decision. Trial averages describe groups of people under a study protocol. They are not a forecast for you.

What the researchers themselves said

We don't publish before-and-after stories on this page. Deep belly fat is invisible — nobody can look at a photo and testify to losing a measured amount of it. Using a personal story to prove a medical claim would be exactly the kind of thing we're trying to protect you from. So here are three short, attributable statements from people who ran or published the studies.

“it can be difficult for patients to reduce visceral fat” — Dr. Ian Neeland, lead investigator of the liraglutide visceral-fat trial, in a University Hospitals release. That trial was funded by Novo Nordisk.

“associated with an inflammatory response and increased cardiometabolic risk” — Dr. Amalia Gastaldelli, describing excess ectopic and visceral fat in the SURPASS-3 MRI announcement. That substudy was funded by Eli Lilly.

“robust changes in body weight, primarily from reduction in fat mass” — the authors' conclusion in the SURMOUNT-1 body-composition paper. The study was sponsored by Eli Lilly; several authors were Lilly employees.

We're telling you who paid for each study on purpose. Most drug trials on this page were funded by the company developing the medicine. That's normal in this field. It's also something you should know while you read the numbers.

Frequently asked questions

Does Ozempic get rid of belly fat?

Semaglutide can reduce overall and abdominal fat, but the SUSTAIN 8 body-composition substudy does not support the viral claim that Ozempic 1.0 mg caused only a 0.81% visceral-fat change. It reported visceral-fat mass falling 0.2 kg with semaglutide versus 0.1 kg with canagliflozin, and the between-group differences were not significant. The stronger obesity-dose CT result came from semaglutide 2.4 mg in STEP 6: −40.0% over 68 weeks. Ozempic is labeled for type 2 diabetes, not chronic weight management.

Is Mounjaro the same as Zepbound for belly fat?

They contain the same active ingredient, tirzepatide, but they have different FDA labels and coverage paths. Mounjaro is the diabetes brand. Zepbound is the chronic weight-management brand used for the available-drug verdict on this page. Do not switch brands or doses without the prescriber and pharmacy confirming the right product.

Is Zepbound or Wegovy better for belly fat?

In the dedicated obesity-dose head-to-head trial, Zepbound produced −18.4 cm waist change versus −13.0 cm for semaglutide 1.7–2.4 mg. An earlier diabetes trial, SURPASS-2, also favored tirzepatide over semaglutide 1.0 mg on waist change, but it used a lower semaglutide dose and a different population. Wegovy 7.2 mg later reported −17.5 cm in its own trial, and no one has compared it directly with Zepbound.

Is Wegovy 7.2 mg better than Zepbound?

No published trial answers that. Wegovy 7.2 mg was tested against placebo and against Wegovy 2.4 mg, not against Zepbound. Anyone claiming a winner is subtracting numbers from two different trials.

Which GLP-1 loses the most inches off the waist?

Retatrutide 12 mg has the largest reported number: 24.1 cm, about 9.5 inches, over 80 weeks in company-released Phase 3 topline data. It is investigational and unavailable outside Lilly trials. Among available FDA-approved medicines tested directly against another active medicine, tirzepatide had the largest result: 18.4 cm, about 7.2 inches, over 72 weeks.

Are GLP-1 pills good for belly fat?

They can reduce waist size and abdominal fat. The Wegovy 25 mg tablet reduced average waist size by 12.2 cm over 64 weeks in its FDA label study. Foundayo's ATTAIN-1 DXA subgroup reported a 19.0% pooled visceral-fat reduction over 72 weeks. Those are separate trials with different outcomes, so do not rank 12.2 cm against 19.0%.

How can I tell if I'm losing visceral fat?

You can't measure it at home. Track your waist-to-height ratio and watch the trend over consistent eight-week gaps. CT and MRI image visceral fat; DXA estimates it. Imaging is a clinical decision, not something to repeat every month to match an article.

Why is my stomach the last place to change?

It may only look that way. Faces and arms show small changes more clearly. Loose skin, bloating, constipation, posture, muscle separation, and where your body stores fat all affect how your middle looks, and none of them reveal exactly what happened around your organs.

Does injecting in my stomach burn stomach fat?

No. The injection site is only where the medicine enters your body. It does not tell the medicine where to remove fat. Nothing on this page targets one body part.

Can I take a GLP-1 if my BMI is normal but my belly bothers me?

That is not the labeled weight-management use. A stomach that sticks out at a normal weight can come from fat distribution, bloating, a hernia, muscle separation, posture, loose skin, constipation, or another cause. See a clinician about the cause first.

How much visceral fat can I lose in three months?

No honest source can give you a personal number. The randomized scan trials in this ledger ran 40 to 72 weeks, and the larger waist trials ran as long as 80 weeks. The first months are often spent increasing the dose. Use three months as an early clinical check-in, not as a promise of a certain scan percentage.

Is compounded tirzepatide the same as Zepbound?

No, and we won't describe them as equivalent. Compounded products are not FDA-approved. As of August 17, 2026, we found no qualifying published visceral-fat scan data for any compounded semaglutide or tirzepatide formulation, so none of the scan numbers on this page can be assigned to one.

Can a smart scale or body-fat scanner measure my visceral fat?

Consumer devices give estimates, not clinical visceral-fat measurements. Use the same device for a rough personal trend if you find it useful, but do not treat its “visceral fat” number as CT, MRI, or proof that a medicine removed a specific amount of deep fat.

Do sit-ups help while I'm on a GLP-1?

Core work strengthens the muscles under the fat, which can be useful. It does not force fat loss from that area. Nothing does — that's what “you can't spot-reduce” means.

Does exercise beat a GLP-1 for visceral fat?

These trials did not test “exercise alone” against a GLP-1. Their placebo groups received diet and activity support, and the five placebo results we placed side by side ranged from −7.3% to +7.4% over 40 to 72 weeks. That does not mean exercise is useless. Activity still matters for your heart, muscle, function, sleep, and long-term weight plan. It means lifestyle counseling and a medicine are not the same tool.

Is retatrutide available for belly fat?

No. It is investigational, with no FDA-approved product and no legal retail path. Lilly says it is legally available only to participants in its clinical trials. Its −24.1 cm waist result and −48.3% Phase 2 MRI visceral-fat result are previews of a possible future medicine, not something to order online.

What if my waist is growing or I have severe belly pain?

Contact a healthcare professional. Do not assume a new or severe abdominal symptom is ordinary fat, gas, constipation, or a normal side effect.

The bottom line

If you want the best GLP-1 for belly fat and visceral fat that is available now, tirzepatide (Zepbound) has the strongest direct evidence — and it earned that from a head-to-head waist result, not from the “40%” stat you keep seeing.

Wegovy 7.2 mg narrowed the cross-trial waist gap to less than half an inch. Nobody has run the comparison that would settle it. Retatrutide posted the biggest waist number of all, but it is still investigational company topline data with nothing approved to buy.

And the visceral-fat percentages floating around the internet cannot be ranked as one clean list. They came from CT, MRI, and DXA; from areas, volumes, kilograms, percentage points, and relative percentages; and from different people under different protocols.

None of these medicines targets your midsection. The effective ones can move it as part of overall weight and fat loss.

What's left is the part only you and your clinician can answer: what your plan covers, whether you'll take a shot or a pill, what side effects you can live with, and whether you can stay on treatment long enough for it to matter.

Still not sure which GLP-1 program is right for you? Take our free 60-second matching quiz.

Sources

Head-to-head, Phase 3, and FDA label evidence

1. Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity — SURMOUNT-5. New England Journal of Medicine. 2025;393(1):26–36. PMID 40353578.
2. Frías JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes — SURPASS-2. New England Journal of Medicine. 2021;385:503–515.
3. Eli Lilly. Retatrutide Phase 3 TRIUMPH-1 topline results. May 21, 2026.
4. FDA. Wegovy current prescribing information, including the 7.2 mg injection and 25 mg tablet.
5. FDA. Zepbound current prescribing information.
6. FDA. Foundayo current prescribing information.
7. STEP UP: once-weekly semaglutide 7.2 mg, Lancet Diabetes & Endocrinology 2025, and Novo Nordisk's STEP UP body-composition summary. NCT05646706.

Visceral-fat imaging studies

1. Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in SURMOUNT-1. Diabetes, Obesity and Metabolism. 2025;27(5):2720–2729. doi:10.1111/dom.16275. See also the published correction, doi:10.1111/dom.70050.
2. Kadowaki T, et al. STEP 6: semaglutide in an East Asian population. Lancet Diabetes & Endocrinology. 2022;10(3):193–206. Follow-up abdominal VFA analysis: PMID 40189961.
3. Wilding JPH, Batterham RL, et al. STEP 1 body-composition analysis.
4. Sanyal AJ, Kaplan LM, Frias JP, et al. Retatrutide Phase 2a MRI substudy in MASLD. Nature Medicine. 2024;30(7):2037–2048.
5. Gastaldelli A, Cusi K, et al. SURPASS-3 MRI substudy. Lancet Diabetes & Endocrinology. 2022;10(6):393–406.
6. Neeland IJ, Marso SP, et al. Effects of liraglutide on visceral and ectopic fat. Lancet Diabetes & Endocrinology. 2021;9(9):595–605.
7. ATTAIN-1 orforglipron trial and Lilly Medical's Foundayo body-composition summary.
8. SUSTAIN 8 body-composition substudy.

Withdrawal, measurement, compounding, and access

1. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: STEP 1 extension.
2. NICE. Guideline NG246: identifying and assessing overweight, obesity, and central adiposity.
3. FDA. Egrifta WR current prescribing information.
4. FDA. Compounding policies as the national GLP-1 supply stabilized.
5. Federal Register. Proposal not to include semaglutide, tirzepatide, and liraglutide on the 503B bulks list and extension of the comment period to July 30, 2026.
6. LillyDirect. Zepbound self-pay options. Verified August 17, 2026.
7. NovoCare. Wegovy savings and self-pay offers. Verified August 17, 2026.
8. Ro. Weight Loss Program pricing. Verified August 17, 2026.
9. Sesame. Online weight-loss program. Verified August 17, 2026.
10. University Hospitals. Interview with Dr. Ian Neeland on the liraglutide visceral-fat trial.
11. Eli Lilly. SURPASS-3 MRI study announcement and investigator statement.

Medical disclaimer: This page is information, not medical advice. It cannot diagnose you, determine your eligibility, choose a medication or dose, or replace a conversation with a licensed clinician. Prescription decisions belong to you and your care team.